FDA: How to Use Galactomannan As Aspergillosis Biomarker

Clinical Trials Advisor
Sponsors seeking to enroll patients in studies of treatments for invasive aspergillosis may use the presence of the molecule galactomannan as a probable indicator of the infection, under an FDA program to qualify biomarkers used in drug development.

To View This Article:


Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00